MNG176
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.484
- MITOTIC_SPINDLE+0.403
- PI3K_AKT_MTOR_SIGNALING+0.361
- WNT_BETA_CATENIN_SIGNALING+0.333
- INTERFERON_ALPHA_RESPONSE+0.300
- UV_RESPONSE_DN+0.285
- PROTEIN_SECRETION+0.274
- G2M_CHECKPOINT+0.265
- TNFA_SIGNALING_VIA_NFKB+0.264
- NOTCH_SIGNALING+0.242
Top 10 suppressed
- KRAS_SIGNALING_DN-0.291
- PANCREAS_BETA_CELLS-0.256
- OXIDATIVE_PHOSPHORYLATION-0.255
- SPERMATOGENESIS-0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.158
- MYOGENESIS-0.153
- COAGULATION-0.139
- ESTROGEN_RESPONSE_LATE-0.116
- GLYCOLYSIS-0.105
- ANGIOGENESIS-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BFA78EE1-F867-4DBD-BE12-2C647C2F53E6 | — | — | 0.841 |
| 2 | 9EE765BF-748F-41B9-926F-FFD0E8C079E3 | — | — | 0.814 |
| 3 | FC2F983B-2530-4886-B759-E2C571E2D068 | — | — | 0.803 |
| 4 | SRR934764 | — | — | 0.798 |
| 5 | SRR934854 | — | — | 0.796 |
| 6 | 90188F36-DEF6-4233-B724-4A25F2D52DAA | — | — | 0.794 |
| 7 | 0CEC1ADC-1E8E-4CAC-8DFD-E1A760064E58 | — | — | 0.788 |
| 8 | 7604968C-689A-458D-96BA-33B163B238F8 | — | — | 0.788 |
| 9 | B2D8ED43-A698-4165-9A96-0ADEEFDA29ED | — | — | 0.781 |
| 10 | 76B4C53E-F764-412D-B238-E01F65CE09C8 | — | — | 0.777 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.484 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.403 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.361 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.333 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.285 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.274 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.265 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.264 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.242 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.229 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.224 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.187 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.174 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.173 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.171 | Inavolisib | — uncovered |
| APOPTOSIS | 0.169 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.169 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.154 | Idelalisib | — uncovered |